ArticleJournal of immunology (Baltimore, Md. : 1950)2010
Ethylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer histocompatibility Y chromosome antigen transplant protection by inhibiting CD154 upregulation.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Inhibition of CD154:CD11b interactions using a novel nanotherapeutic improves allograft survival.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Nanoparticle-based T cell immunoimaging and immunomodulatory for diagnosing and treating transplant rejection.Heliyon · 2024Review
- Cutting edge of immune response and immunosuppressants in allogeneic and xenogeneic islet transplantation.Frontiers in immunology · 2024Review
- Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity.JCI insight · 2018Article
- ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives.Current transplantation reports · 2017Article
- Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice.Transplantation · 2017Article
- In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.Advanced drug delivery reviews · 2017Review
- An antigen-encapsulating nanoparticle platform for TNanomedicine : nanotechnology, biology, and medicine · 2017Article
- Concise Review: Mechanisms Behind Apoptotic Cell-Based Therapies Against Transplant Rejection and Graft versus Host Disease.Stem cells (Dayton, Ohio) · 2016Review
- Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.Biomaterials · 2016Article
- Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2015Review
- Overcoming immunological barriers in regenerative medicine.Nature biotechnology · 2014Article
- Exploiting apoptosis for therapeutic tolerance induction.Journal of immunology (Baltimore, Md. : 1950) · 2013Review
- Engineering antigens for in situ erythrocyte binding induces T-cell deletion.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.Critical reviews in immunology · 2013Review
- Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.Nature biotechnology · 2012Article
- Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
In humans and certain strains of laboratory mice, male tissue is recognized as nonself and destroyed by the female immune system via recognition of histocompatibility Y chromosome Ag (Hya). Male tissue destruction is thought to be accomplished by CTLs in a helper-dependent manner. We show that graft protection induced with the immunodominant Hya-encoded CD4 epitope (Dby) attached to female splenic leukocytes (Dby-SPs) with the chemical cross-linker ethylenecarbodiimide significantly, and often indefinitely, prolongs the survival of male skin graft transplants in an Ag-specific manner. In contrast, treatments with the Hya CD8 epitopes (Uty-/Smcy-SPs) failed to prolong graft survival. Dby-SP-tolerized CD4(+) T cells fail to proliferate, secrete IFN-gamma, or effectively prime a CD8 response in recipients of male grafts. Ag-coupled splenocyte treatment is associated with defective CD40-CD40L interactions as demonstrated by the observation that CD4 cells from treated animals exhibit a defect in CD40L upregulation following in vitro Ag challenge. Furthermore, treatment with an agonistic anti-CD40 Ab at the time of transplantation abrogates protection from graft rejection. Interestingly, anti-CD40 treatment completely restores the function of Dby-specific CD4 cells but not Uty- or Smcy-specific CD8 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.